News for Samsung Biologics Co.,Ltd. (207940.KS)

Recorded Q1'25 consolidated revenue of KRW 1.3 trillion Recorded Q1'25 consolidated operating profit of KRW 486.7 billion Company expected to maintain steady growth momentum in 2025 driven by enhanced operational efficiency and diverse service offerings INCHEON, South Korea, April 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2025.

PR NewswireINCHEON, South Korea, Feb. 12, 2025 - Company receives leadership status and A- rating for efficient water resources management- Rec

Recorded Q4'24 consolidated revenue of KRW 1.26 trillion Recorded FY'24 consolidated revenue of KRW 4.55 trillion Poised for further growth with expanded capacity and new service offerings INCHEON, South Korea, Jan. 22, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the fourth quarter and fiscal year 2024.

PR NewswireINCHEON, South Korea, Jan. 14, 2025 - The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April- Samsung Bio

Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development

Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery

Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON, South Korea, Dec. 17, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its continued recognition by the Dow Jones Sustainability World Index (DJSI), a globally recognized benchmark for evaluating the sustainability performance of over 2,500 publicly traded companies.

PR NewswireINCHEON, South Korea, Dec. 3, 2024 INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract deve

The company will provide manufacturing services through 2031 in deals worth over USD 668 million Samsung Biologics' cumulative contract value for 2024 surpasses USD 4 billion with latest deals INCHEON, South Korea, Nov. 20, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced a series of manufacturing deals with a Europe-based pharmaceutical company.

Samsung Biologics earns ISO certifications in recognition of business excellence

The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDMO partner INCHEON, South Korea , Nov. 8, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO) today announced it has achieved ISO 37301:2021 certification for the first time. The company also renewed certifications for upgraded ISO 27001:2022 and ISO 27017:2015 standards. The certifications were presented by the British Standards Institution (BSI) during a ceremony held at Samsung Biologics' headquarters.

Recorded Q3'24 consolidated revenue of KRW 1.2 trillion Recorded Q3'24 consolidated operating profit of KRW 338.6 billion Continued business expansion through strong competitive edge in speed and execution INCHEON, South Korea, Oct. 23, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the third quarter of fiscal year 2024.

Baron Emerging Markets Fund gained 9.07% (Inst) during the third quarter of 2024. Click here to read the full commentary.

/PRNewswire/ -- The biologics CDMO market size is estimated to grow by USD 13.26 billion from 2022 to 2027, at a CAGR of 13.97%, according to a recent market...

NOTICE OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 31, 2023 ________________________ ... | April 20, 2023

/PRNewswire/ -- The "Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2029" & "Pharmaceutical Excipients Global Market - Forecast To 2029"...

/PRNewswire/ -- The biologics CDMO market is estimated to accelerate at a CAGR of 13.97% and register an incremental growth of USD 13.26 billion during the...

/PRNewswire/ -- Global Biologics CDMO Market 2023-2027 The analyst has been monitoring the biologics CDMO market and is forecast to grow by $13.26 bn during...

/PRNewswire/ -- The "Biologics CDMO Secondary Packaging Market Size and Share Analysis by Type, Primary Package Type - Global Industry Revenue Estimation and...